University of California, Los Angeles

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).

897 total trials 158 currently recruiting 622 completed early-phase tilt top decile by trial count

University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.

University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

897 total, page 14 of 18

COMPLETED Phase 1

Chronic Moderate Sleep Restriction in Older Adults

NCT01642719

COMPLETED Phase 4

Vilazodone for Treatment of Geriatric Depression

NCT01608295

COMPLETED NA

Promoting Sleep and Healthy Aging Research Study (PRO-SHARE)

NCT01641263

COMPLETED NA

Financial Incentives and Text Messaging to Improve African American Womens' Glycemic Control

NCT02384265

COMPLETED Phase 2

Combination Treatment for Augmenting Language in Children With ASD

NCT02574741

COMPLETED NA

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

NCT02067507

COMPLETED

Addressing Attitudes to Improve Use of Protective Headwear in Older Adults

NCT01582464

TERMINATED Phase 4

Anesthetic Techniques in EP Patients

NCT02664922

COMPLETED NA

Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity

NCT01755962

COMPLETED Phase 1

Impact of Grape Consumption on Brain Metabolism and Cognitive Function

NCT01573611

COMPLETED NA

Screening, Brief Intervention, and Referral to Treatment for Offenders

NCT01683643

COMPLETED NA

Schema, Emotion, and Behavior Therapy for Children

NCT01784263

COMPLETED NA

Web-Based Weight Management for Individuals With Mental Illness

NCT01324973

COMPLETED Phase 2

18-Month Study of Memory Effects of Curcumin

NCT01383161

COMPLETED Phase 2

Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora

NCT01861964

COMPLETED Phase 2

Varenicline for Methamphetamine Dependence

NCT01365819

COMPLETED Phase 1

Effect of Mindfulness Training on Sleep and Inflammation Among Older Adults With Sleep Problems

NCT01534338

COMPLETED NA

Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals

NCT01510665

COMPLETED NA

eRT Remote Health Monitoring

NCT01495780

COMPLETED NA

Equinox Personal Coaching Versus Self-Directed Exercise

NCT01778153

COMPLETED NA

Schema, Emotion and Behavior-Based Therapy for School Children

NCT02010086

COMPLETED NA

A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)

NCT01573949

COMPLETED Phase 1

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

NCT01501084

COMPLETED

Physician-Patient Communication Project

NCT01530867

COMPLETED NA

Early Intervention for Youth at Risk for Bipolar Disorder

NCT01483391

COMPLETED Phase 4

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736

COMPLETED NA

Better Effectiveness After Transition - Heart Failure

NCT01360203

COMPLETED Phase 2

Pomegranate Extract and Memory

NCT01950221

COMPLETED Phase 2

Cocaine Use Reduction With Buprenorphine

NCT01402492

COMPLETED

Home Electrocardiogram (ECG) Monitoring After Heart Transplantation

NCT01365806

COMPLETED NA

Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control

NCT01402453

COMPLETED NA

Effects of Avocado When Added to a Meat Patty on Inflammation in Healthy Men

NCT01397071

COMPLETED

Comparison of Markers of Kidney Function

NCT01403766

COMPLETED NA

Centralized Off-Site Adherence Enhancement Program

NCT01409655

COMPLETED NA

Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder

NCT01368510

COMPLETED Phase 1

Q-Trial in Patients With Hepatitis C

NCT01438320

COMPLETED Early Phase 1

Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)

NCT01388530

TERMINATED Phase 2

Pedaling Exercises for Disability and Activity Limitations

NCT01391949

TERMINATED Phase 4

Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor

NCT01519765

COMPLETED Phase 1

Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking

NCT01359709

TERMINATED NA

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

NCT01319045

COMPLETED

Comparing Calories at Fast Food Restaurants

NCT01357434

COMPLETED NA

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125

TERMINATED Phase 3

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT02634606

COMPLETED Early Phase 1

Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms

NCT01671150

COMPLETED

Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.

NCT01517516

COMPLETED Phase 3

Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis

NCT01299961

COMPLETED Phase 1

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

NCT02597647

COMPLETED

Quantitative Sensory Testing and Analysis of Post Inguinal Hernia Surgery Pain

NCT01534429

COMPLETED NA

A Parenting and Self-Care Intervention for HIV Infected Mothers

NCT01586988

← Previous Page 14 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 112
Phase 2 82
Phase 3 22
Phase 4 76

What is open in the University of California, Los Angeles pipeline

158 recruiting of 897 indexed (18% open); 622 completed (69%).

Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Los Angeles: open-pipeline peers nationwide

Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20% Total trials Recruiting share University of California, Los AngelesIndiana UniversityHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders Network
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 897 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, Los Angeles page

897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.

  • 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.